{"product_id":"evolenthealth-five-forces-analysis","title":"Evolent Health Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Overview to Strategy Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eEvolent Health faces moderate supplier leverage, rising buyer price sensitivity, specialized provider competition, and growing substitution risks from tech-enabled care models—creating a complex strategic landscape that demands deeper analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Clinical Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe limited pool of oncology and cardiology specialists constrains Evolent’s specialty programs, with hospitals and PE-backed physician groups competing for talent and driving up clinical oversight costs.\u003c\/p\u003e\n\u003cp\u003eBy late 2025, U.S. shortages—American Medical Association data show cardiology shortfalls near 8% and oncology vacancies up to 10% in key markets—let suppliers demand higher pay and preferred contract terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCloud Infrastructure and Technology Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvolent relies on AWS and Microsoft Azure to host its population-health platforms; in 2024 cloud infrastructure spending grew 18% and accounted for roughly 12–15% of similar digital-health firms’ OPEX, so supplier leverage is high.\u003c\/p\u003e\n\u003cp\u003eHigh switching costs and dependency on provider uptime and security raise risk: 99.99% SLAs and advanced security features are table stakes, and outages can hit revenue and quality metrics quickly.\u003c\/p\u003e\n\u003cp\u003eMultiple providers exist, but deep integration of Evolent’s proprietary algorithms into specific cloud stacks limits price negotiation, keeping supplier bargaining power elevated.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical and Claims Data Aggregators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvolent’s predictive analytics depend on high-quality feeds from clinical and claims data aggregators and EHR vendors, so these suppliers wield significant leverage over accuracy of cost-saving projections. In 2025, consolidation left roughly 4–6 major national aggregators, cutting alternative sources by about 40% since 2020 and increasing supplier bargaining power. Lost or incomplete data can swing projected savings by 10–25%, exposing Evolent to revenue and performance risk tied to vendor terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCybersecurity and Compliance Consultants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCybersecurity and compliance consultants command high bargaining power as healthcare breaches rose 55% from 2019–2024 and average breach costs hit $10.1M in 2023, forcing Evolent to buy premium security and legal services to protect contracts with major health plans.\u003c\/p\u003e\n\u003cp\u003eThese specialist firms serve the whole sector, keep premium rates, and are indispensable for Evolent’s operational continuity and trust maintenance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBreach cost: $10.1M (2023)\u003c\/li\u003e\n\u003cli\u003eHealthcare breaches +55% (2019–2024)\u003c\/li\u003e\n\u003cli\u003eHigh-demand specialists = premium pricing\u003c\/li\u003e\n\u003cli\u003eSuppliers vital to retain major health-plan contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI and Machine Learning Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpthe push toward ai-driven clinical pathways forces evolent to secure senior software engineers and data scientists us median scientist salary was about in top hires command plus equity keeping labor costs elevated margins under pressure.\u003e\u003cpthis talent can jump to big tech startups or payer firms so evolent must offer cash plus equity flexibility and raising r expense as a share of revenue in health-tech hiring competition rose year-over-year.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh salaries: median $120k (2024)\u003c\/li\u003e\n\u003cli\u003eTop hires: $200k+ + equity\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D hiring growth: ~18% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eTalent mobility raises retention costs, cuts margin\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier power, rising talent\/cloud \u0026amp; breach costs squeeze margins and pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold high bargaining power: specialist clinicians, consolidated data aggregators (4–6 national players by 2025), cloud providers (AWS\/Azure; cloud OPEX ~12–15%), and premium cybersecurity firms drive costs and risk; talent costs (median data scientist $120k in 2024; top hires $200k+) and breach costs ($10.1M in 2023) compress margins and limit contract flexibility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eData aggregators\u003c\/td\u003e\n\u003ctd\u003e4–6 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCloud OPEX\u003c\/td\u003e\n\u003ctd\u003e12–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian data scientist\u003c\/td\u003e\n\u003ctd\u003e$120k (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBreach cost\u003c\/td\u003e\n\u003ctd\u003e$10.1M (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Evolent Health, uncovering competitive drivers, customer and supplier power, entry barriers, substitutes, and emerging threats that shape pricing, profitability, and strategic positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces snapshot for Evolent Health—quickly gauge provider\/buyer leverage, entrant threats, substitutes, and competitive rivalry to support strategic moves and M\u0026amp;A decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Major Health Plans\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvolent’s 2024 revenue remained concentrated: the top five payers and health systems accounted for roughly 65% of revenue, giving these customers strong leverage to push down service fees and demand better renewal terms.\u003c\/p\u003e\n\u003cp\u003eLarge payers can pressure margins via pricing, scope cuts, or insourcing; historically contract renewals saw single-digit fee concessions that trimmed operating margin by several hundred basis points.\u003c\/p\u003e\n\u003cp\u003eAs of 2025, losing one major payer (10–20% revenue) would materially hit EBITDA and market cap—an event likely to trigger analyst downgrades and stock volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for Proven Return on Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCustomers now demand rigorous proof that Evolent’s programs cut medical spend and boost outcomes; in 2024 payors cited metrics showing average medical cost reductions of 5–12% as deal prerequisites. \u003c\/p\u003e\n\u003cp\u003eA growing share of Evolent’s revenue—about 20–35% per recent client contracts—is tied to hitting clinical benchmarks, so payment is at risk if targets miss. \u003c\/p\u003e\n\u003cp\u003eBuyers push these performance metrics to transfer financial risk onto Evolent, squeezing margins and raising pressure on care-management effectiveness. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThreat of Backward Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge payers like UnitedHealth Group and Humana, with 2024 revenues of $352B and $88B respectively, can invest in in-house population health and specialty care platforms; if Evolent’s per-member-per-month fees rise above payer build costs (often \u0026lt;$10–$20 PMPM for initial setups), payers may backward integrate. This risk forces Evolent to prove its platform cuts total medical spend—Evolent reported 2024 care-management savings averaging 4.5%—and to keep pricing competitive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Healthcare Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConsolidation among US health insurers—Aetna\/CVS (2018), Cigna\/Express Scripts (2018), and Centene’s 2022 expansion—has cut the buyer pool so the top five payers now control roughly 60% of commercial enrollment (2024 CMS\/HIX data), giving large payers outsized leverage over pricing and tech standards; Evolent faces few, powerful customers who demand deep integration, tight SLAs, and compressed margins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTop-five payers ≈60% commercial enrollment (2024)\u003c\/li\u003e\n\u003cli\u003eM\u0026amp;A reduced mid-size buyers by ~20% since 2018\u003c\/li\u003e\n\u003cli\u003ePayers push outcome-based, risk-sharing contracts\u003c\/li\u003e\n\u003cli\u003eEvolent must invest in scalable, certified integrations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for Technology Only Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpwhile deep clinical partnerships in show stickiness evolent reported revenue resilience with recurring contracts commoditized tech-only offerings face higher churn as clients can switch to lower-cost saas for data viz or claims processing.\u003e\n\u003cpthis dynamic pressures evolent to prioritize integrated clinical services where higher margins and longer contract terms reduce churn boost lifetime value.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~70% recurring clinical revenue (2024)\u003c\/li\u003e\n\u003cli\u003eTech-only services face double-digit churn risk vs integrated care\u003c\/li\u003e\n\u003cli\u003eStrategy: shift to high-value clinical integrations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pwhile\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvolent at Risk: Concentrated Payer Power, Outcome Pricing \u0026amp; Margin Squeeze\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvolent faces high customer bargaining power: top five payers\/health systems ~65% revenue (2024), top-five payers ≈60% commercial enrollment (2024), ~70% recurring clinical revenue (2024); 20–35% contracts tied to outcomes; losing one large payer (10–20% revenue) would materially cut EBITDA; payers can insource if PMPM \u0026gt;$10–$20; outcome-based pricing squeezes margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-5 revenue share\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-5 enrollment\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring clinical revenue\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutcome-tied revenue\u003c\/td\u003e\n\u003ctd\u003e20–35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical PMPM build cost\u003c\/td\u003e\n\u003ctd\u003e$10–$20\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eEvolent Health Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Evolent Health Porter’s Five Forces analysis you’ll receive immediately after purchase—no placeholders or samples; it’s the fully formatted, ready-to-use document delivered for instant download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747178656121,"sku":"evolenthealth-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/evolenthealth-five-forces-analysis.png?v=1772195667","url":"https:\/\/matrixbcg.com\/products\/evolenthealth-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}